# Dextenza (dexamethasone) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dexamethasone

> The FDA approved Dextenza (dexamethasone), sponsored by OCULAR THERAPEUTIX, INC (OCUL), on November 30, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Dextenza (dexamethasone) |
| Codes |  |
| Sponsor | OCULAR THERAPEUTIX, INC (OCUL) https://sec-api.dev/companies/ocul/catalysts |
| Indications | ataxia-telangiectasia |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 21, 2016: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22208742_2018_Orig1s000OtherActionLtrs.pdf%22

### July 10, 2017: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22208742_2018_Orig1s000OtherActionLtrs.pdf%22

### November 30, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208742 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20181130, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22

### October 7, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208742 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20211007, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22

### April 7, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208742 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ataxia-Telangiectasia.
- First seen 2025-07-16, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-277523): "Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Quince remains on track to report topline results for our pivotal Phase 3 NEAT clinical trial evaluating our lead asset eDSP (encapsulated dexamethasone sodium phosphate) for the treatment of Ataxia-Telangiectasia (A-T) in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/qncx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-277523): "Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1662774/000119312525277523/qncx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106536): "Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/qncx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-277529): "We expect to report topline results from the Phase 3 NEAT clinical trial in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1662774/000119312525277529/qncx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106535): "We expect to report topline results from the Phase 3 NEAT clinical trial in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1662774/000095017025106535/qncx-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-159886): "Quince remains on track to deliver topline results in the first quarter of 2026 and positive results will lead to an NDA submission in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1662774/000119312525159886/d71020dex991.htm

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-06-11, last confirmed 2026-09-25.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-063497): "cemsidomide + dexamethasone + elranatamab2 S T A T U S Initiation of Phase 1b Trial w/ Two Arms Expected in 1H 2027" https://www.sec.gov/Archives/edgar/data/1662579/000162828026063497/septembercorporatedeck_f.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-042365): "Cemsidomide + dexamethasone + elranatamab3 S T A T U S Initiation of Phase 1b Trial w/ Two Arms Expected in 1H 2027" https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/june2026corporatedeck.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dexamethasone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dextenza (dexamethasone) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dexamethasone

```bibtex
@misc{secapidev_pdufa_dexamethasone_20261116,
  title        = {Dextenza (dexamethasone) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dexamethasone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dexamethasone_20261116","title":"Dextenza (dexamethasone) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dexamethasone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
